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Abstract
Innate lymphoid cells (ILCs), a newly identified member of the lymphoid population, play a critical role in the transition
from innate to adaptive immunity in host defense. ILCs are important in mucosal barrier immunity, tissue homeostasis,
and immune regulation throughout the body. Significant alterations in ILC responses in lung diseases have been
observed and reported. Emerging evidence has shown that ILCs are importantly involved in the pathogenesis
and development of a variety of lung diseases, i.e., helminth infections, allergic airway inflammation, and airway
hyper-responsiveness. However, as a tissue-resident cell population, the role of ILCs in the lung remains poorly
characterized. In this review, we discuss the role of ILCs in lung diseases, the mechanisms underlying the ILC-mediated
regulation of immunity, and the therapeutic potential of modulating ILC responses.
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Background
Innate lymphoid cells (ILCs) are emerging as an import-
ant cell population of innate immunity and play complex
roles in lymphoid tissue formation, tissue remodeling,
tissue stromal cell homeostasis, and regulation of host
responses to infection and inflammation. Compared to
adaptive lymphocytes, ILCs are relatively rare in lymph-
oid tissue, but they populate barrier surfaces, such as the
skin, intestine, and lung, as well as in adipose and some
mucosal-associated lymphoid tissues [1–3]. Compared
to typical lymphoid cells, ILCs are characterized by three
main features: 1) the absence of recombination activat-
ing gene (RAG)-dependent rearrangement of antigen
receptors; 2) a lack of phenotypical markers of myeloid
cells and dendritic cells; and 3) particular lymphoid
morphology [4]. The prototypes of the ILCs family are
natural killer (NK) cells and lymphoid tissue-inducer
(LTi) cells, which were discovered in 1975 and 1997,
respectively [5, 6]. Recently, other members of the ILC
family have been characterized. Based on their pheno-
typical and functional characteristics, ILCs are catego-
rized into three subgroups. ILC1s include NK cells,
which produce interferon-γ (IFN-γ). ILC2s produce type
2 cytokines, e.g. IL-5 and IL-13, and are dependent on
GATA-binding protein 3 (GATA3) and retinoic acid
receptor-related orphan receptor-α (ROR-α) for their de-
velopment and function. ILC3s include all ILC subtypes
that produce IL-17 and/or IL-22, and they depend on
the transcription factor ROR-γt for their development
and function (Fig. 1) [2, 7].
The molecular and cellular components of the innate
and adaptive immune systems influence and regulate
both lung homeostasis and the development of lung dis-
eases. The emerging ILC family has been shown to have
critical roles in the initiation, modulation, and resolution
of lung diseases. Studies using mouse models indicated
that ILCs play an important role in the remodeling of
damaged lung tissue following influenza virus infection,
contribute to the exacerbated allergic asthma induced by
viruses [8–10], promote the release of inflammatory
mediators in allergic lung inflammation [11] and are
involved in the induction of pulmonary fibrosis [12].
Human studies showed that ILC responses in pulmonary
diseases are substantially altered. These findings suggest
broad roles of ILCs in lung physiological and patho-
logical process. In this review, we address the origin,
development, and heterogeneity of ILCs, and the roles of
ILCs in lung homeostasis and diseases; we will then
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discuss potential novel strategies of intervention in lung
diseases by targeting ILCs.
Development and heterogeneity of the ILC family
Common lymphoid progenitors (CLPs) differentiate
into cells of the adaptive immune system, i.e., T cells
and B cells; however, a subset of CLPs gives rise to
ILCs [13, 14]. ILCs initially develop in the fetal liver
and later develop in the adult bone marrow [14–16].
The development of ILCs from CLPs is independent
of the RAG-dependent rearrangement of antigen re-
ceptors, but is regulated by several transcription factors
[3, 17, 18]. The differentiation of ILCs from CLPs re-
quires transcriptional factors, including inhibitor of
DNA binding 2 (Id2), nuclear factor interleukin-3 regu-
lated (NFIL3), and thymocyte selection-associated high-
mobility group box protein (TOX) [2, 3, 16, 19–24].
Firstly, two precursors, including NK cell precursors
(NKps) and common helper innate lymphoid precur-
sors (CHILPs), are derived from CLPs. NKps develop
into NK cells, and CHILPs give rise to all other ILCs
through a process that requires T-cell factor 1 (TCF1),
interleukin 7 (IL-7) [24] and GATA3 [25–28]. From
CHILPs, several distinct progenitors expressing α4β7
integrin develop into LTi cells [14]. Another group of
CHILPs can give rise to ILC progenitors (ILCps) [15].
The development of ILCps from CHILP depends on
promyelocytic leukemia zinc finger (PLZF), a tran-
scriptional repressor involved in the cell cycle control,
development and differentiation of myeloid cells [15].
ILCps transiently express abundant PLZF, a transcription
factor associated with NKT cell development [29, 30],
suggesting an interaction between ILCps and NKT cells.
Studies have identified a population of human CD34+
hematopoietic progenitor cells (HPCs) in human bone
marrow and peripheral blood that express ROR-γt and se-
lectively differentiate toward ILC3s. HPCs are located in
the tonsils and intestinal lamina propria (LP) and are able
to differentiate into either NK cells or LTi-like cells
through a process influenced by aryl hydrocarbon receptor
Fig. 1 Development and heterogeneity of the ILC family. ILCs develop from distinct progenitors in the fetal liver or bone marrow and then develop
into mature ILCs in the periphery. Different transcription factors and cytokines are involved in the development of the three groups of mature ILCs. All
ILCs develop from CLPs, which can differentiate into NKps or CHILPs. CHILPs can further differentiate into LTi cells through α4β7+ populations or into
other ILC populations through differentiation into ILCps. ILC1s express T-bet, are responsive to IL-12, and produce IFN-γ and/or TNF. ILC2s
highly express GATA3, are responsive to IL-25, IL-33 and TSLP, and produce IL-4, IL-5, IL-9, IL-13 and amphiregulin. ILC3s express ROR-γt,
are responsive to IL-1β and IL-23, and produce IL-17 and/or IL-22
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(Ahr) ligands, stem cell factor (SCF), and IL-15 [31].
Under the regulation of different transcription factors and
interleukins, NKps, ILCps, and α4β7+ progenitors differ-
entiate into three groups of ILCs, termed Group 1 ILCs
(ILC1s), Group 2 ILCs (ILC2s) and Group 3 ILCs (ILC3s)
(Fig. 1) [1–3, 7].
ILC1s respond to IL-12, constitutively express T-bet,
and produce effector cytokines, such as interferon
(IFN)-γ and tumor necrosis factor (TNF) [16, 32, 33].
The differentiation of ILC1s from ILCps requires eome-
sodermin (Eomes), T-bet, IL-15, and IL-7. Based on the
difference in the expression of the products and require-
ments for the regulators, ILC1s can be divided into at
least three subsets. One subset includes conventional
NK cells, which require Eomes and IL-15, but not IL-7
or T-bet, for development from NKps [16]. Another sub-
set of ILC1s, CD103+ intraepithelial ILC1s, develop from
an as yet unknown precursor in a process that requires
T-bet, NFIL3, and Id2, but not IL-15; ILC1s express
Eomes [33]. Further studies also identified a subset that
develops from CHILPs and ILCps in a T-bet- and IL-15-
dependent, but IL-7-independent, manner and does not
express Eomes (Fig. 1) [16, 32].
ILC2s respond to the cytokines IL-25, IL-33, and
thymic stromal lymphopoietin (TSLP); they constitu-
tively express high levels of GATA3; and they produce
the effector cytokines IL-4, IL-5, IL-9, IL-13, and
amphiregulin [8, 34, 35]. ILC2 development requires
GATA3 [27, 28], ROR-α [36, 37], and the transcription
factors Gfi1 and Bcl11b [38–40]. Furthermore, GATA3
is required for the functional maturation and mainten-
ance of ILC2s [41–44], and Bcl11b serves as a upstream
regulator of the transcriptional factor Gfi1 to maintain
Gfi1 expression in mature ILC2s. Mature ILC2s populate
the healthy skin, lungs, and adipose tissue of humans
and mice [8, 34, 35, 45–48], and they are the most
common group in the lung [49].
ILC3s respond to IL-1β, IL-6, and IL-23; they consti-
tutively express ROR-γt, and they produce the effector
cytokines IL-17 and/or IL-22 [50–53]. LTi cells are
members of the ILC3s, which develop independently
of PLZF-dependent ILCps. They express CCR6 and/or
CD4 and secrete IL-22 and IL-17 and lymphotoxin
(LT) [54]. A subset of adult ILC3s develop from ILCps
and can be divided into two groups, NCR- ILC3s and
NCR+ ILC3s, according to the expression of natural
cytotoxicity receptors (NCRs, e.g., NKp46 and NKp44).
These cells can express IFN-γ and IL-22, and their
development requires T-bet and Ahr [54–58]. T-bet+
ILC3s are nearly exclusively located in the skin and
intestinal lamina propria, whereas LTi-like ILC3s are
positioned in the intestine and lymphoid tissues. How-
ever, ILC3s with a unique phenotype, which express
Thy1, stem cell antigen 1 (SCA-1), ROR-γt and IL-
23R, can develop in some inflammatory contexts in the
liver and intestine [59, 60].
Inter-transfer between different types of ILCs has been
reported. The ILC2 population can differentiate into IL-
17-producing ILC3-like cells [61]. Many factors are in-
volved in the functional transfer between ILC2s and
ILC3s. Bcl11b seems to be a determinant for the main-
tenance of the ILC2 phenotype because Bcl11b-/- ILC2s
lose their ILC2 functions and gain ILC3s functions.
Interestingly, in response to the protease allergen papain,
these cells expand and produce ILC3, but not ILC2,
cytokines and cause increased airway infiltration of neu-
trophils rather than eosinophils. Bcl11b has a direct role
in repressing the expression of the gene encoding the
ILC3s transcription factor Ahr, which is an ILC3 lineage
transcription factor, thus contributing to the silencing
of ILC3 genes in ILC2s. In Bcl11b-/- mice, the ILC2s
down-regulated ILC2s genes, such as Gata3 and Il1rl1
(encoding IL-33 receptor), and up-regulated Rorc and
the ILC3 genes. Recent studies reported plasticity
between different ILC groups. ILC3 subsets could
down-regulate ROR-γt expression in humans and mice,
leading to dominant T-bet expression and sustained
IFN-γ expression, both of which are known characteris-
tics of ILC1s [32, 54, 55]. These transient cells were
termed ex-ILC3s [16, 32, 54, 55]. It is currently uncer-
tain how to define and classify these populations.
ILCs in the lungs
ILCs in both lymphoid and non-lymphoid organs are
tissue-resident cells that are locally renewed and ex-
panded in response to acute environmental challenges.
The maintenance of ILCs depends on their self-renewal
ability in different microenvironments and physiological
conditions [49].
ILCs have been identified in the human and mouse
lungs and airways [8]. In the mouse lung, ILC2s are the
main cell type of ILCs. However, ILC2s are a relatively
rare population, comprising 2-3 × 104 cells in the lung of
a naïve mouse and representing 0.4-1 % of the total live
cells in the lung [8]. In human lung tissue, approxi-
mately 60 % of ILCs are ILC3s, and the most abundant
ILC3s are NCR- ILC3s. In the contrast, the percentages
of ILC1s and ILC2s are 10 % and 30 %, respectively [62].
ILC2s, although small in number, play important roles
in innate immunity and disease progressions by se-
creting type 2 cytokines and tissue growth factors.
Furthermore, in humans, LC3-like cells are observed
in the bronchoalveolar lavage fluid of individuals with
asthma [63].
Studies have shown that more than 95 % of the lung-
resident ILCs are of host origin and are maintained
and expanded locally under physiologic or pathological
conditions [49]. During lung infections, the local
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expansion of resident ILCs is followed by the increased
hematogenous recruitment and redistribution of ILCs.
ILCs maintain lung homeostasis
Maintenance of the epithelial barrier function in re-
spiratory tract mucosal sites is critical to limit exposure
to physiological and immunological stimuli [64, 65]. Re-
cent findings suggest that ILCs are a crucial cell lineage
for maintaining airway barrier integrity and tissue
homeostasis after influenza virus infection [8]. ILC2-in-
duced mediators including IL-4, IL-5, IL-9, IL-13 and
amphiregulin are important for maintaining lung homeo-
stasis (Fig. 2) [8, 66]. Mouse and human studies have
shown that lung-resident ILC2s are observed in the bron-
choalveolar space and can thus be collected from the
bronchoalveolar lavage fluid. ILC2 depletion impairs
epithelial integrity and lung function following influenza
virus infection. Studies further showed that ILC2
depletion resulted in an impaired ability to generate
hyper-plastic epithelial cells and led to substantial epithe-
lial degeneration and necrosis [8]. IL-22, which is mainly
produced by ILC3s in the lung, is also involved in the
Fig. 2 The role of the ILC family in lung homeostasis, cell-cell interactions and tissue repair. a In response to infection or allergen exposure, epithelial
cell- and myeloid cell-derived IL-25, IL-33 and TSLP elicit ILC2s responses in the lung. ILC2 responses can be enhanced by basophil-derived IL-4 or mast
cell-derived PGD2. Activated ILC2s can subsequently promote IL-5-mediated eosinophil recruitment, IL-13-mediated AMac differentiation,
or MHCII-mediated enhancement of Th2 cell responses, resulting in allergy and fibrosis. However, ILC1-derived IL-27 and IFN-γ can antagonize the
function of ILC2s and type 2 innate immune responses. Furthermore, ILC2s proliferate in response to lymphoid-derived IL-2 and produce
large amounts of Th2 cytokines, including IL-5, IL-6 and IL-13. IL-5 and IL-6 regulate B cell antibody production and the self-renewal of B1
cells. b After infection in the lung, airway epithelial cells are damaged and produce IL-33. ILC2s respond to IL-33 and produce amphiregulin, which
promotes the repair of the airway epithelium. Together with autocrine IL-9 production, the IL-33 produced by macrophages, DCs, mast cells, NKTs and
lymphoid cells enhances the repair function of ILCs. c In the innate inflammatory response in the lung, alveolar type II cells produce IL-33 and TSLP,
which synergistically induce ILC2s to produce IL-5 and IL-13. IL-5 and IL-13 are known to promote mucus production
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maintenance of lung epithelial cell function and in the
negative regulation of lung inflammation [67, 68]. A re-
cent study suggested that during lung homeostasis, ILC2s
use the IL-9 module to coordinate epithelial cell mainten-
ance [69]. In the chitin-induced innate inflammatory re-
sponse of the lung, alveolar type II cells produce TSLP
and IL-33, which synergistically induce an interferon regu-
latory factor 4 (IRF4)-IL-9 program in ILC2s. Additionally,
autocrine IL-9 promotes the production of IL-5 and IL-
13, which are required for optimal epithelial responses in
the conducting airways [69]. Moreover, IL-5 and IL-13
were known to promote mucus production and tissue
repair [66, 70]. Thus, ILC2s contribute to barrier surveil-
lance and epithelial responses.
Interaction of ILCs with other cells in the lung
In the lung, ILCs interact with other cells, including
local epithelial cells, NKT cells, myeloid cells and granu-
locytes, to form an immune system network.
Studies have suggested that epithelial cell-derived me-
diators are important for ILC regulation. For example,
epithelial cell- or myeloid cell-derived IL-25, IL-33, and
TSLP can elicit ILC2 responses after allergen, chemical,
or helminth parasite exposure or influenza virus infec-
tion [8, 9, 34, 35, 46, 71–73]. ILC2 responses in the lung
can be enhanced by basophils, which produce IL-4 in
mouse models of protease allergen-induced airway in-
flammation [74]. In humans, mast cells can promote
ILC2 responses directly by producing prostaglandin D2
(PGD2) [75]. Furthermore, the epithelial cell-derived
cytokine TGF-β plays a central role in enhancing ILC
chemoactivity and generating the pulmonary immune
response (Fig. 2) [67]. IL-33 is a chromatin-associated
nuclear cytokine that is abundantly expressed in epithe-
lial and endothelial cells and thought to be released only
upon cellular damage or necrotic cell death [76, 77].
ILCs in the airway lumen respond to TGF-β through the
receptor TGF-βRII [78]. IL-33 is over-expressed in the
lungs of patients with idiopathic pulmonary fibrosis,
asthma, and lung inflammation, and the over-expression
of IL-33 is associated with ILC2 expansion [79]. IL-33
promotes ST2-dependent lung fibrosis by inducing
macrophage activation and enhancing ILC2s expansion.
Recent studies have shown that IL-33 is also expressed
by NKT cells, alveolar macrophages, DCs, and mast
cells [9, 80–82]. During influenza virus infection in
mice, enhanced release of IL-33 from NKT cells oc-
curred concomitantly with enhanced IL-5 production
by ILC2s [82].
Moreover, T cells have been shown to interact with
ILCs in the lung. ILCs were unable to induce worm
expulsion in Rag2−/− mice, which lack B and T cells, in-
fected with helminths or challenged with the protease
papain [83]. In mice lacking T cells, the number of ILC2s
was reduced to the uninfected levels, despite the con-
tinuous presence of intestinal worms. These observa-
tions suggest that adaptive immune cells, such as T cells,
promote ILC2 expansion and survival. Studies have also
shown that ILC2s influence antigen-specific T cell re-
sponses. Adoptive transfer of wild type or Il13−/− ILC2s
into Il17br−/− mice, in which the secretion of T-cell-
derived IL-13 was delayed, restored the antigen-specific
T cell production of IL-13. The results suggest that
ILC2s regulate antigen-specific T cell responses and en-
hance T cell cytokine production in an IL-13-independent
manner [83]. In vitro co-culture of lung ILC2s with CD4+
T cells induced the enhanced proliferation of the CD4+
T cells and the production of Th2 cytokines [83]. In
papain-induced lung inflammation, IL-9 was produced
by ILCs, and the production of IL-9 is dependent on IL-
2 produced by T cells and B cells [84]. Furthermore, by
increasing T helper 2 cell (Th2) responses, ILC2s can
promote chronic inflammation in mice. This occurs ei-
ther by migration of activated DCs to the lung draining
lymph node and subsequent Th2 cell priming in re-
sponse to IL-13 [85] or by the direct interactions with
CD4+ T cells in a major histocompatibility complex
class II (MHCII)-dependent manner [86, 87].
Crosstalk between B cell and ILCs in the lung has also
been reported. The fat-associated lymphoid clusters
(FALC)-derived ILC2s proliferate in response to IL-2
and produce large amounts of Th2 cytokines, including
IL-5, IL-6 and IL-13. IL-5 and IL-6 regulate B cell anti-
body production and self-renewal of B1 cells [88–90].
Other studies showed that FALC-derived ILC2s support
the self-renewal and expansion of B1 and B2 cells and
enhance the production of the IgA, IgM, IgG1, and IgE
antibody classes [34, 71, 72, 91]. However, a discrepancy
was noticed in the results from different studies; there-
fore, further studies are needed to clarify the relationship
between B cells and ILCs.
Studies have shown that IL-27 and IFN-γ, which can
be released by ILC1s, antagonize the function of ILC2s
and type 2 innate immune responses; in ILC2s lacking
the IFN-γ receptor, ILC2-mediated lung inflammation
was enhanced. The transcription factor STAT1 seems
important in mediating the suppressive effects of IL-27
and IFN-γ on ILC2 functions [92, 93]. However, some
other studies have shown that type I interferons directly
and negatively regulate ILC2s in mice and humans by
activating the transcription factor ISGF3 and the subse-
quent cytokine production, cell proliferation, and cell
death [92]. Furthermore, although ILC3s are normally
absent in the lungs of healthy mice [8], in the lungs of a
mouse model of obesity-induced asthma, ILC3s expand
in response to NLRP3-dependent production of IL-1β by
macrophages [63]. Nonetheless, these findings suggest
an interaction between ILC1s and ILC2s.
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ILCs mediate lung tissue repair
The recovery of lung tissue following injury is critical for
restoring lung homeostasis and is a complex process in-
volving multiple cellular and molecular regulators, such
as interleukins (IL-1β, IL-2, IL-4, IL-9, and IL-13), che-
mokines (MCP-1), growth factors (TGF-β, KGF, and
HGF), and extracellular matrix proteins (MMP-1, MMP-
7, and MMP-9) [94–96]. Tissue remodeling following
acute injury requires a balanced regulation between
acute inflammation, the recruitment of immune cells,
and epithelial cell proliferation. Failure of either appro-
priate cell proliferation or limitations in these repair
responses can induce the loss of lung function, impair
tissue integrity, and induce chronic inflammation or
tissue fibrosis [94, 95]. It was found that the lung ILC
population was critical for the repair and remodeling of
damaged tissue following influenza virus infection [8].
Genome-wide transcriptional profiling revealed that lung
ILCs express a number of genes associated with wound
healing and tissue repair, including the extracellular
matrix proteins decorin, aspirin and dermatopontin and
epidermal growth factor family members, such as
amphiregulin. Depletion of ILC2s did not impair innate
immunity in the mice following influenza infection, but
it did result in the loss of airway epithelial integrity,
decreased lung function, and impaired airway remodel-
ing [8]. This repair function was restored by adminis-
tration of amphiregulin, the product of lung ILCs. In
the study of N. brasiliensis infection in mouse lungs,
autocrine IL-9 production contributes to the survival
of activated ILC2s, amplifies ILC2-mediated amphire-
gulin production, and promotes tissue repair [96].
Therefore, ILC2s represent a major ILC population in
the lung, which promotes the recovery of damaged
lung tissue after infection.
The role of ILCs in lung diseases
Current studies have recently emphasized the complex
role of ILCs and their alterations in disease-association
studies of patients and experimental models, such as
lung transplantation, influenza virus infection, allergic
asthma, chronic rhinosinusitis and chronic obstructive
pulmonary disease (COPD).
In influenza virus infection, a population of ILCs that
express CD90, CD25, CD127, and T1-ST2 was identified
in the mouse and human lungs [8]. A mouse study
showed that ILCs accumulated in the lung in response
to IL-33 and immune-mediated tissue damage after
influenza virus infection [8].
Asthma is a prevalent disease of chronic inflammation
in which the Th2 cytokines IL-4, IL-5, and IL-13 are all
tightly linked to the pathogenesis of asthma. IL-4
induces IgE production by B cells [97], IL-5 activates
eosinophils and recruits them to the lung [98], and IL-
13 increases mucus production [98]. Murine studies
have shown that ILC2s accumulated in the lung and sig-
nificantly contributed to IL-5 and IL-13 production in
allergic asthma [99]. ILCs, including NK cells and ILC2s,
participate in the regulation of allergic airway responses.
NK cells were highly activated in patients with severe
asthma and interacted with autologous eosinophils to
promote their apoptosis. Both NK cells and ILC2s can
decrease airway inflammation and mediate eosinophilic
inflammation [75]. However, not all the functions of
ILC2s are protective, as these cells also mediate patho-
logical injury in a mouse model of virus-mediated exacer-
bation of allergic asthma. In animal models of allergic
asthma, ILC2-derived IL-13 is an essential inducer of
mucus hypersecretion and inflammation [100, 101]. IL-13
also causes inflammatory responses in monocytes and
eosinophils, mucus cell metaplasia, airway fibrosis, and
airway obstruction [102].
Chronic rhinosinusitis is a typical type 2 inflammatory
disease associated with IL-13 release from ILC2s. Hu-
man ILC2s express a prostaglandin D2 receptor named
chemoattractant receptor expressed on Th2 cells
(CRTH2), and elevated numbers of CRTH2+ ILCs were
observed in the nasal polyps of patients with chronic
rhinosinusitis compared to control subjects [35, 77].
These cells responded to IL-2, IL-25 and IL-33, and their
function depends on IL-13 [35]. Furthermore, anti-
interleukin-13 therapy improves the lung function of
patients with severe asthma who had a pretreatment
profile consistent with interleukin-13 activity [103].
COPD is characterized by a chronic inflammation of
the airways. The formation of lymphoid follicles and
neutrophilic airway inflammation are two characteristics
of COPD [104, 105]. In a mouse study, ILC accumula-
tion in lung tissue was observed during acute exacerba-
tions of COPD (AECOPD) [106]. A tendency toward a
higher frequency of NCR- ILC3 was observed in the
lungs of patients with COPD compared with the con-
trols [62]. Additionally, IL-17A and IL-22, which are
produced by NCR- ILC3s, contribute to the formation of
lymphoid follicles [107, 108]. Neutrophil elastase and
IL-5 levels are increased in AECOPD patients [109].
IL-13 mRNA levels are increased ~30-fold in sputum
eosinophils and endothelial cells in AECOPD patients
compared to normal control subjects [110]. Import-
antly, IL-5 and IL-13 were produced by ILC2s and
are responsible for COPD exacerbation [111]. Al-
though there is no study that reported the functions
of ILCs in COPD, it is strongly tempting to speculate
that ILC2s and ILC3s are activated in COPD patients.
Potential therapeutic modulation of ILCs
Based on the findings showing that ILCs play an import-
ant role in lung homeostasis and diseases, there is an
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urgent need to investigate whether the modulation of
ILC responses is a practical therapeutic strategy that
could provide a clinical benefit. Indeed, various thera-
peutic strategies have been developed that aim to
modify ILC development, cell-cell crosstalk, effector
molecules, cytokine-receptor pathways, and tissue re-
pair functions and maintenance. On the other hand,
ILCs can be a biomarker for several diseases. Because
many therapies were used to treat patients with mul-
tiple sclerosis or Crohn's disease, options are available
for use to determine whether these strategies also work
in patients with lung disease. A therapeutic example is
the treatment of patients with multiple sclerosis with
daclizumab, which is a humanized monoclonal antibody
against α chain of the interleukin-2 receptor (IL-2Ra;
CD25). Daclizumab modulates ILC responses by de-
creasing the number of ILCs by modifying the cells’
phenotypes and shifting the cells toward a NK cell
lineage [112].
However, it is important to consider how the thera-
peutic strategies may affect the pathologic versus pro-
tective functions of ILCs. Some methods include
targeting molecules that are critical for the development
and migration of ILCs, e.g. α4β7 and MAdCAM-1. A
clinical study revealed that Vitamin D can inhibit cyto-
kine production and integrin α4β7 expression in human
ILCs [113]. However, retinoic acid has antagonistic ef-
fects, which worked synergistically with other cytokines
to induce the expression of the gut-homing integrin
α4β7 in ILCs. Therefore, the balance between Vitamins
A and D influences human ILC responses and acts as an
critical factor in the function of ILCs in diseases, such as
allergic inflammation [113]. Furthermore, some strat-
egies target the effector molecules of ILCs, such as TNF-
TNFR, IL-17-IL-17R, IFN-γ and IL-13-IL-13R. Many
anti-Interleukin-17 or anti-Interleukin-23 receptor anti-
bodies, which target the IL-23-IL-17 pathway, have
beneficial effects on psoriasis and rheumatoid arthritis in
experimental mouse models and patients [114–119].
However, in patients with Crohn's disease, the blockade
of IL-17 was ineffective and caused higher rates of ad-
verse events. In some cases, anti-IL-17 therapy resulted
in increased susceptibility to fungal infections and en-
hanced disease [120–123]. Because ILC2s can regulate
eosinophilic inflammation, a recent study showed that
ILC2s acted as a surrogate biomarker of eosinophilic air-
way inflammation in patients. Moreover, this biomarker
may distinguish the asthmatic patients with mild to
moderate asthma who are most likely to receive benefits
from therapeutics targeting Th2 inflammation [124].
Therefore, novel therapeutics are necessary for select-
ively modulating protective versus pathologic ILCs
responses, including novel small-molecule inhibitors of
transcription factors.
Despite these advances, further studies are required to
reveal the ILC responses in defined patient populations
and to fully reveal how ILC function can be modulated
to limit human disease.
Conclusions
Our knowledge of ILC development and regulation and
their roles in lung diseases has been greatly advanced
by recent research. However, a better definition of in-
nate immune cells, i.e., a universal consensus on the
markers for ILCs in humans and mice, is needed. At
the cellular and molecular level, the interactions be-
tween ILCs and other immune and tissue cells, as well
as the mechanisms involved in these interactions, need
to be addressed. A critical appraisal of translational
studies is also expected, including the determination of
the expression profiles of these cells in patients and the
ILC responses to currently used medications. Further-
more, several questions regarding the potential plasti-
city of ILC populations, ILCs’ novel functions, and the
regulatory pathways affecting ILC responses should be
addressed using animal approaches. Knowledge of ILC
biology and their roles in resting conditions and disease
states will be necessary for us to better understand the
mechanisms of lung diseases and to develop novel
therapeutic options for these diseases.
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